Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future

Download All
In this program, experts review the recommended guidelines for managing operable, advanced, or metastatic renal cell carcinoma, including the latest data on emerging therapies and adverse event management. Download the slidsesets from a live CME/CE/CPE-certified satellite symposium presented in Chicago at ASCO 2022 and read an expert commentary.
Katy Beckermann, MD, PhD
person default
Naomi B. Haas, MD
Eric Jonasch, MD

ClinicalThought

Drs Katy Beckermann, Naomi Haas, and Eric Jonasch provide key updates on the use of available regimens in renal cell carcinoma across the adjuvant, first-line, and second-line settings.

Katy Beckermann, MD, PhD person default Naomi B. Haas, MD Eric Jonasch, MD Released: August 1, 2022
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AVEO Oncology
Eisai Inc.
Exelixis
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings